Fig. 3.

Durability of response. Responder rates are summarised according to patients’ blinded maintenance treatment group. Missing values were imputed using NRI. Placebo data are not shown as there were only two patients in the placebo group who were week 16 PASI 75 responders and no patients in the placebo group were week 16 PASI 90 responders. ^aIncludes patients who received CZP 200 mg Q2W and CZP 400 mg Q4W during maintenance. CZP certolizumab pegol, NRI non-responder imputation, PASI 75/90 at least 75%/90% improvement from baseline in Psoriasis Area and Severity Index, Q2W every 2 weeks, Q4W every 4 weeks